Effect of low dose naloxone on the immune system function of a patient undergoing video-assisted thoracoscopic resection of lung cancer with sufentanil controlled analgesia — a randomized controlled trial

Yun, Lin; Miao, Zhimin; Wu, Yue; F, Ge; Wen, Qingping

doi:10.1186/s12871-019-0912-6

Cited by 10 publications

(13 citation statements)

References 35 publications

(42 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, pharmacogenomics was used to predict potential drugs. Since naloxone has been approved for clinical treatment of lung cancer [ 10 ], our results may support the use of CREB1 gene status as an ovarian cancer biomarker and precision treatment of OV patients with naloxone.…”

Section: Introductionsupporting

confidence: 61%

Identification of Novel Biomarkers and Candidate Drug in Ovarian Cancer

Lin

Chu

et al. 2021

JPM

View full text Add to dashboard Cite

This paper investigates the expression of the CREB1 gene in ovarian cancer (OV) by deeply excavating the gene information in the multiple databases and the mechanism thereof. In short, we found that the expression of the CREB1 gene in ovarian cancer tissue was significantly higher than that of normal ovarian tissue. Kaplan–Meier survival analysis showed that the overall survival was significantly shorter in patients with high expression of the CREB1 gene than those in patients with low expression of the CREB1 gene, and the prognosis of patients with low expression of the CREB1 gene was better. The CREB1 gene may play a role in the occurrence and development of ovarian cancer by regulating the process of protein. Based on differentially expressed genes, 20 small-molecule drugs that potentially target CREB1 with abnormal expression in OV were obtained from the CMap database. Among these compounds, we found that naloxone has the greatest therapeutic value for OV. The high expression of the CREB1 gene may be an indicator of poor prognosis in ovarian cancer patients. Targeting CREB1 may be a potential tool for the diagnosis and treatment of OV.

show abstract

Section: Introductionsupporting

confidence: 61%

Identification of Novel Biomarkers and Candidate Drug in Ovarian Cancer

Lin

Chu

et al. 2021

JPM

View full text Add to dashboard Cite

show abstract

“…As for the reason for R2 resection, 59.5% ( n = 22) cases were due to bulky metastatic lymph nodes which could not be completely resected. Additionally, postoperative immunosuppression may further contribute to the progression of residual disease 22,23 . For patients with R2 resection in our study, even postoperative radiotherapy could not make up for compromised patient survival following incomplete resection.…”

Section: Discussionmentioning

confidence: 65%

“…Additionally, postoperative immunosuppression may further contribute to the progression of residual disease. 22,23 For patients with R2 resection in our study, even postoperative radiotherapy could not make up for compromised patient survival following incomplete resection. Therefore, for most of the patients with clinical stage N2, especially those with bulky metastatic lymph nodes, the conclusion is that optimal treatment is concurrent chemoradiotherapy rather than surgery.…”

Section: Discussionmentioning

confidence: 70%

Postoperative radiotherapy for pathological stageIIIA‐N2 non‐smallcell lung cancer with positive surgical margins

Yuan¹,

Men

Kang³

et al. 2020

Thoracic Cancer

View full text Add to dashboard Cite

Background: The aim of this study was to evaluate the efficacy of postoperative radiotherapy (PORT) in stage pIIIA-N2 non-small cell lung cancer (NSCLC) patients with positive surgical margins. Methods: Between January 2003 and December 2015, patients who had undergone lobectomy or pneumonectomy plus mediastinal lymph node dissection or systematic sampling in our single institution were retrospectively reviewed. Those with pIIIA-N2 NSCLC and positive surgical margins were enrolled into the study. The Kaplan-Meier method was used for survival analysis, and the log-rank test was used to analyze differences between the groups. Univariate and multivariate analyses using Cox proportional hazards regression models were performed to evaluate potential prognostic factors for OS. Statistically significant difference was set as P < 0.05. Results: Of all the 1547 patients with pIIIA-N2 NSCLC reviewed, 113 patients had positive surgical margins, including 76 patients with R1 resection and 37 with R2 resection. The median overall survival (OS) was 28.3 months in the PORT group and 22.6 months in the non-PORT group (P = 0.568). Subset analysis showed that for patients with R1 resection, the median OS was 52.4 months in the PORT group which was nonsignificantly longer than that of 22.6 months in the non-PORT group (P = 0.127), whereas PORT combined with chemotherapy could significantly improve OS, with a median OS of 52.4 months versus 17.2 months (P = 0.027). For patients with R2 resection, PORT made no significant difference in OS (17.6 vs. 63.8 months, P = 0.529). Conclusions: For pIIIA-N2 NSCLC patients with positive surgical margins, PORT did not improve OS, but OS was improved in those patients who underwent R1 resection combined with chemotherapy.

show abstract

“…Indeed, it was reported that opioid receptor antagonists, e.g., NAL, at low doses, enhance the release of endogenous opioids, as well as upregulate opioid receptors [ 81 , 82 ]. Interestingly, low-dose NAL administered to a patient under sufentanil-controlled analgesia increased levels of opioid growth factor (OGF), which is an endogenous opioid, and natural killer (NK) cells, a critical player in innate immunity [ 83 , 84 ]. Other studies also showed that OGF increases numbers of NK cells [ 85 , 86 , 87 ].…”

Section: Discussionmentioning

confidence: 99%

Iron Acquisition Proteins of Pseudomonas aeruginosa as Potential Vaccine Targets: In Silico Analysis and In Vivo Evaluation of Protective Efficacy of the Hemophore HasAp

et al. 2022

View full text Add to dashboard Cite

Background: Pseudomonas aeruginosa (PA) is a Gram-negative pathogen responsible for fatal nosocomial infections worldwide. Iron is essential for Gram-negative bacteria to establish an infection. Therefore, iron acquisition proteins (IAPs) of bacteria are attractive vaccine targets. Methodology: A “Reverse Vaccinology” approach was employed in the current study. Expression levels of 37 IAPs in various types of PA infections were analyzed in seven previously published studies. The IAP vaccine candidate was selected based on multiple criteria, including a high level of expression, high antigenicity, solubility, and conservation among PA strains, utilizing suitable bioinformatics analysis tools. The selected IAP candidate was recombinantly expressed in Escherichia coli and purified using metal affinity chromatography. It was further evaluated in vivo for protection efficacy. The novel immune adjuvant, naloxone (NAL), was used. Results and discussion: HasAp antigen met all the in silico selection criteria, being highly antigenic, soluble, and conserved. In addition, it was the most highly expressed IAP in terms of average fold change compared to control. Although HasAp did excel in the in silico evaluation, subcutaneous immunization with recombinant HasAp alone or recombinant HasAp plus NAL (HasAP-NAL) did not provide the expected protection compared to controls. Immunized mice showed a low IgG2a/IgG1 ratio, indicating a T-helper type 2 (Th2)-oriented immune response that is suboptimal for protection against PA infections. Surprisingly, the bacterial count in livers of both NAL- and HasAp-NAL-immunized mice was significantly lower than the count in the HasAp and saline groups. The same trend was observed in kidneys and lungs obtained from these groups, although the difference was not significant. Such protection could be attributed to the enhancement of innate immunity by NAL. Conclusions: We provided a detailed in silico analysis of IAPs of PA followed by in vivo evaluation of the best IAP, HasAp. Despite the promising in silico results, HasAp did not provide the anticipated vaccine efficacy. HasAp should be further evaluated as a vaccine candidate through varying the immunization regimens, models of infection, and immunoadjuvants. Combination with other IAPs might also improve vaccination efficacy. We also shed light on several highly expressed promising IAPs whose efficacy as vaccine candidates is worthy of further investigation.

show abstract

Effect of low dose naloxone on the immune system function of a patient undergoing video-assisted thoracoscopic resection of lung cancer with sufentanil controlled analgesia — a randomized controlled trial

Cited by 10 publications

References 35 publications

Identification of Novel Biomarkers and Candidate Drug in Ovarian Cancer

Identification of Novel Biomarkers and Candidate Drug in Ovarian Cancer

Postoperative radiotherapy for pathological stageIIIA‐N2 non‐smallcell lung cancer with positive surgical margins

Iron Acquisition Proteins of Pseudomonas aeruginosa as Potential Vaccine Targets: In Silico Analysis and In Vivo Evaluation of Protective Efficacy of the Hemophore HasAp

Contact Info

Product

Resources

About